November 13, 2024

Air Pollution Tied to Head, Neck Cancers

The strongest correlation between PM2.5 exposure and head and neck cancer incidence occurred at a 5-year lag period, suggesting a potential temporal relationship between air pollution exposure and cancer development.

Conexiant

November 12, 2024

Lp(a) and LDL-C: Separate ASCVD Risk Factors

Conexiant

November 12, 2024

Young Adults Face Rising Colorectal Cancer Rates

Conexiant

November 11, 2024

Early Data for Phase 1 TNBC Vaccine Trial

Novel vaccine targeting alpha-lactalbumin, a protein expressed in 70% of triple-negative breast cancers but otherwise found only in lactating breast tissue, shows early immune response in Phase 1 trial.

Conexiant

November 11, 2024

AF Burden Trends Linked to Stroke Risk

Temporal AF burden trends offer a novel edge in stroke prediction, outperforming traditional risk scores with a predictive AUC of 0.726 for ischemic events, a new study finds.

Conexiant

November 08, 2024

Ensuring an Inclusive Environment for Female Minority Oncologists

Acts of discrimination by her superiors and colleagues at an academic cancer center in New York City prompted Coral Olazagasti, MD, a native of Puerto Rico, to launch a study examining gender disparit...

The ASCO Post

November 08, 2024

Study Finds Cisplatin Shortage Led to Treatment Alternatives for Head and Neck Cancer, Significantly Increasing Cost

The alternative use of the monoclonal antibody cetuximab during the shortage of cisplatin in the treatment of head and neck cancer resulted in a 16% total cost increase, leading to a 144-fold increase...

The ASCO Post

November 08, 2024

Nivolumab Plus Ipilimumab in Aggressive Thyroid Carcinoma

In a single-institution phase II study reported in JAMA Oncology, Sehgal et al found evidence of activity of the combination of nivolumab and ipilimumab in patients with aggressive thyroid carcinoma.

The ASCO Post

November 08, 2024

COVID-19 & Flu Vaccines Study: Comparable Safety

Simultaneous COVID-19 and flu vaccination shows no increase in moderate or severe reactions—study reveals safety of one-stop immunization approach.

Conexiant